Picture1.png
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Picture1.png
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Picture1.png
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics announces publication in Blood Cancer Journal
Picture1.png
Autolus Announces Pricing of Underwritten Offering
February 08, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Announces Pricing of Underwritten Offering
Picture1.png
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  
February 08, 2024 05:45 ET | Autolus Therapeutics plc; BioNTech SE
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Picture1.png
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics announces publication in ACS Chemical Biology
Picture1.png
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Picture1.png
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Picture1.png
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023 20:30 ET | Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Picture1.png
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)